{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:50:37Z","timestamp":1790880637815,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40268-023-00441-7","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T11:02:19Z","timestamp":1697194939000},"page":"421-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Analytical and Functional Similarity of the Biosimilar Candidate ABP\u00a0654 to Ustekinumab Reference Product"],"prefix":"10.1007","volume":"23","author":[{"given":"Greg","family":"Cantin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kuhns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"441_CR1","unstructured":"STELARA\u00ae (ustekinumab). United States prescribing information. Horsham: Janssen Biotech, Inc.; 2020."},{"issue":"4","key":"441_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1517\/14712591003724670","volume":"10","author":"C Ryan","year":"2010","unstructured":"Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune disease. Expert Opin Biol Ther. 2010;10(4):587\u2013604. https:\/\/doi.org\/10.1517\/14712591003724670.","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"441_CR3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719\u201329. https:\/\/doi.org\/10.1038\/nm.3895.","journal-title":"Nat Med"},{"key":"441_CR4","unstructured":"European Medicines Agency. EPAR ustekinumab (Stelara), 2019. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara. Accessed 5 Dec 2022."},{"issue":"3","key":"441_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40259-017-0218-5","volume":"31","author":"R Markus","year":"2017","unstructured":"Markus R, Liu J, Ramchandani M, Landa D, Born T, Kaur P. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31(3):175\u201387. https:\/\/doi.org\/10.1007\/s40259-017-0218-5.","journal-title":"BioDrugs"},{"key":"441_CR6","unstructured":"US Food and Drug Administration. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product guidance for industry. April 2015. Available at: https:\/\/www.fda.gov\/media\/135612\/download. Accessed 5 Dec 2022."},{"key":"441_CR7","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. 23 October 2014. CHMP\/437\/04 Rev. 1. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf. Accessed 5 Dec 2022."},{"key":"441_CR8","unstructured":"US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. April 2015. Available at: https:\/\/www.fda.gov\/media\/82647\/download. Accessed 5 Dec 2022."},{"issue":"2","key":"441_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-020-01256-5","volume":"80","author":"H Kim","year":"2020","unstructured":"Kim H, Alten R, Avedano L, Dignass A, Gomollon F, Greveson K, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99\u2013113. https:\/\/doi.org\/10.1007\/s40265-020-01256-5.","journal-title":"Drugs"},{"key":"441_CR10","unstructured":"US Food and Drug Administration. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations guidance for industry. May 2019. Available at: https:\/\/www.fda.gov\/media\/159261\/download. Accessed 5 Dec 2022."},{"issue":"4","key":"441_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4161\/bioe.25067","volume":"4","author":"I Abraham","year":"2013","unstructured":"Abraham I, Sun D, Bagalagel A, Altyar A, Mohammed A, Tharmarajah S, et al. Biosimilars in 3D: definition, development and differentiation. Bioengineered. 2013;4(4):203\u20136. https:\/\/doi.org\/10.4161\/bioe.25067.","journal-title":"Bioengineered"},{"issue":"2","key":"441_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4161\/mabs.3.2.15005","volume":"3","author":"M McCamish","year":"2011","unstructured":"McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011;3(2):209\u201317. https:\/\/doi.org\/10.4161\/mabs.3.2.15005.","journal-title":"MAbs"},{"issue":"11","key":"441_CR13","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1002\/jps.22686","volume":"100","author":"Y Jiang","year":"2011","unstructured":"Jiang Y, Li C, Nguyen X, Muzammil S, Towers E, Gabrielson J, et al. Qualification of FTIR spectroscopic method for protein secondary structural analysis. J Pharm Sci. 2011;100(11):4631\u201341. https:\/\/doi.org\/10.1002\/jps.22686.","journal-title":"J Pharm Sci"},{"issue":"11","key":"441_CR14","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1002\/jps.22695","volume":"100","author":"CH Li","year":"2011","unstructured":"Li CH, Nguyen X, Narhi L, Chemmalil L, Towers E, Muzammil S, et al. Applications of circular dichroism (CD) for structural analysis of proteins: qualification of near- and far-UV CD for protein higher order structural analysis. J Pharm Sci. 2011;100(11):4642\u201354. https:\/\/doi.org\/10.1002\/jps.22695.","journal-title":"J Pharm Sci"},{"issue":"3","key":"441_CR15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1006\/bbrc.1996.1295","volume":"225","author":"X Fan","year":"1996","unstructured":"Fan X, Sibalic V, Niederer E, Wuthrich RP. The proinflammatory cytokine interleukin-12 occurs as a cell membrane-bound form on macrophages. Biochem Biophys Res Commun. 1996;225(3):1063\u20137. https:\/\/doi.org\/10.1006\/bbrc.1996.1295.","journal-title":"Biochem Biophys Res Commun"},{"key":"441_CR16","doi-asserted-by":"crossref","unstructured":"Chow V, Mytych DT, Das S, Franklin J. Pharmacokinetic similarity of ABP 654, an ustekinumab biosimilar candidate: results from a randomized, double-blind study in healthy subjects. Clin Pharmacol Drug Dev. 2023;12(9):863\u2013873. https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.","DOI":"10.1002\/cpdd.1301"},{"issue":"4","key":"441_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.4161\/mabs.24725","volume":"5","author":"KM Hutterer","year":"2013","unstructured":"Hutterer KM, Hong RW, Lull J, Zhao X, Wang T, Pei R, et al. Monoclonal antibody disulfide reduction during manufacturing: Untangling process effects from product effects. MAbs. 2013;5(4):608\u201313. https:\/\/doi.org\/10.4161\/mabs.24725.","journal-title":"MAbs"},{"key":"441_CR18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jpba.2014.10.023","volume":"102","author":"T Wang","year":"2015","unstructured":"Wang T, Liu YD, Cai B, Huang G, Flynn GC. Investigation of antibody disulfide reduction and re-oxidation and impact to biological activities. J Pharm Biomed Anal. 2015;102:519\u201328. https:\/\/doi.org\/10.1016\/j.jpba.2014.10.023.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"441_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cpt.2785","volume":"113","author":"E Guillen","year":"2023","unstructured":"Guillen E, Ekman N, Barry S, Weise M, Wolff-Holz E. A data driven approach to support tailored clinical programs for biosimilar monoclonal antibodies. Clin Pharmacol Ther. 2023;113(1):108\u201323. https:\/\/doi.org\/10.1002\/cpt.2785.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"441_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","volume":"3","author":"JM Benson","year":"2011","unstructured":"Benson JM, Peritt D, Scallon BJ, Heavner GA, Shealy DJ, Giles-Komar JM, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535\u201345. https:\/\/doi.org\/10.4161\/mabs.3.6.17815.","journal-title":"MAbs"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00441-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00441-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00441-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T04:15:31Z","timestamp":1700885731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00441-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00441-7","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,13]]},"assertion":[{"value":"11 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Amgen Inc., Thousand Oaks, CA, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Greg Cantin, Qian Liu, Bhavana Shah, Scott Kuhns, Mats Wikstr\u00f6m, Shawn Cao, and Jennifer Liu are employees and stockholders of Amgen Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"There is a plan to share data. This may include de-identified individual patient data for variables necessary to address the specific research question in an approved data-sharing request, and also related data dictionaries, study protocol, statistical analysis plan, informed consent form, and\/or clinical study report. Data sharing requests relating to data in this manuscript will be considered after the publication date and (1) this product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or (2) clinical development discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for these data. Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study\/studies in scope, endpoints\/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). Complete details are available at\n                      \n                      . In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labeling. A committee of internal advisors reviews requests. If not approved, a Data Sharing Independent Review Panel may arbitrate and make the final decision. Requests that pose a potential conflict of interest or an actual or potential competitive risk may be declined at Amgen\u2019s sole discretion and without further arbitration. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and\/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication, availability of data, and material code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}